Renaissance Capital logo

Passage Bio Priced, Nasdaq: PASG

Preclinical biotech developing gene therapies for rare CNS disorders.

Industry: Health Care

First Day Return: +23.3%

We are a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system, or CNS, disorders with limited or no approved treatment options. Our vision is to become the premier genetic medicines company by developing and ultimately commercializing therapies that dramatically and positively transform the lives of patients suffering from these life-threatening disorders. To achieve our vision, we have assembled a world-class team whose members have decades of collective experience in genetic medicines and rare disease drug development and commercialization. The field of genetic medicine is rapidly expanding and we believe we have a differentiated approach to developing treatments for rare, monogenic CNS disorders that enables us to select and advance product candidates with a higher probability of technical and regulatory success. We have entered into a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, headed by Dr. James Wilson, a leader in the genetic medicines field.

Passage Bio (PASG) Performance

Created with Highcharts 10.3.2Chart context menuPASG vs. IPO Index (IPOUSA)May 2020Sep 2020Jan 2021May 2021Sep 2021Jan 2022May 2022Sep 2022Jan 2023May 2023Sep 2023Jan 2024May 2024Sep 2024Jan 2025May 20250%+ 100%+ 200%-100%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index